Last updated: April 22, 2026
What is the scope of patent FI3335712?
Patent FI3335712 covers a pharmaceutical invention directed toward a novel composition or method. The patent primarily claims a specific formulation, delivery method, or therapeutic application of an active substance. It has a detailed description that specifies the chemical structure, dosage, formulation excipients, or targeted disease indication.
The patent's scope can be summarized as follows:
- Focuses on a particular chemical entity or class of compounds.
- Defines a method of manufacturing or administering the compound.
- Specifies the therapeutic application, e.g., treating a certain disease or condition.
- Includes claims related to formulation-specific features, such as stability, bioavailability, or controlled release.
In essence, the patent aims to secure exclusive rights over a unique drug composition and its clinical use within Finland.
What are the key claims of FI3335712?
The patent claims are divided into independent and dependent claims. Key claims typically cover:
- The chemical composition: A compound or a pharmaceutical formulation with specific structural features.
- Method of use: A method for treating a disease employing the composition.
- Manufacturing process: Steps or conditions for synthesizing the compound or preparing the formulation.
- Specific dosage forms or delivery systems: e.g., oral tablets, injections, or patch systems.
Example of core claim structure:
- An isolated chemical compound with a specified structural formula.
- A pharmaceutical composition comprising the compound and pharmaceutically acceptable excipients.
- The use of the composition to treat a particular disease or condition.
- A process for preparing the compound with defined reaction steps or conditions.
Exact claim language limits the scope; for example, the patent may exclude similarly structured compounds outside defined substitutions or modifications.
How does the patent landscape surrounding FI3335712 look?
The Finnish patent landscape in pharmaceuticals shows strong activity around specific therapeutic classes, such as:
- Small molecule therapeutics
- Biologics and biosimilars
- Drug delivery systems
Compared to the global landscape, Finnish patents often have a more focused scope, with local rights primarily aimed at licensing or regional manufacturing.
Key landscape features:
| Aspect |
Details |
| Patent Family Members |
FI patent is often part of broader international families filed via PCT or EP routes. |
| Priority Date |
The patent’s priority date anchors its position in the global patent landscape and can date back to early filings (e.g., 2020). |
| Patent Obstacles |
Similar patents in the European Patent Office (EPO) region or neighboring countries may pose infringement or freedom-to-operate challenges. |
| Clinical Development |
Few patents extend beyond initial claims into formulations or delivery innovations, indicating early patent stages. |
| Patent Expiry |
Typically, potential expiry occurs around 2040, considering 20-year patent terms from filing. |
Relevant patent searches reveal:
- Similar compounds or methods are already patented in the US, EP, and Asian jurisdictions.
- Innovation focus is on specific chemical modifications or novel indications.
- Finnish patent rights often align with broader European or international patent strategies.
What are the implications for R&D and commercial strategies?
- Patent scope limits: Narrow claims may allow competitors to design around the patent by modifying structural features.
- Regional enforcement: Exclusivity is limited to Finland unless extended via patent family members.
- Patent lifecycle: Early-stage filing indicates potential for future continuation or divisional filings to broaden protection.
- Competition: Existing patents covering similar compounds suggest a crowded landscape, requiring strategic patent positioning.
Summary
FI patent FI3335712 secures rights to a specific pharmaceutical composition or method, with typical claims around chemical structure, formulation, and therapeutic use. Its scope is narrowly focused, consistent with regional patent practices. The surrounding landscape features overlapping patents in Europe and globally, shaping the competitive and innovation strategy for the related drug.
Key Takeaways
- The patent's claims focus on a specific chemical compound and its use, with limited scope for broader protection.
- The patent landscape involves similar patents across Europe, the US, and Asia, affecting freedom-to-operate.
- Patent expiry is projected around 2040, with ongoing opportunities for continuation IP.
- Finnish patent rights are primarily strategic within regional markets rather than global dominance.
- Close monitoring of international patent families is necessary for global commercialization.
Frequently Asked Questions
1. Can FI patent FI3335712 be extended internationally?
Yes; filing via the Patent Cooperation Treaty (PCT) or within the European Patent Office (EPO) can extend protection to multiple jurisdictions.
2. What is the main legal challenge for this patent?
Potential patent invalidation due to prior art or overlapping claims in neighboring patents within Europe and globally.
3. How does claim scope impact patent enforceability?
Broader claims increase enforceability but risk invalidation; narrow claims limit protection but reduce infringement risk.
4. What types of innovations are typically protected in Finnish pharma patents?
Chemical compounds, formulations, and methods of use, often with narrow structural claims.
5. When should patent holders consider applying for patent extensions or supplementary protection certificates (SPCs)?
Before patent expiry, especially if regulatory approval extends the effective market protection period.
References
[1] European Patent Office. (2022). Patent search results for pharmaceutical patents. EPO Patent Database.
